drugset / Trial / NCT06430190

Peginterferon α-2b Combined CO2 Laser in Condylomata Acuminata

NCT06430190

Unknown 30 enrolled Zhangyu Bu
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a prospective, randomized, open-label, controlled study, aiming to enroll 30 patients with Condylomata Acuminata. The study consists of two phases: a treatment phase (Weeks W1-W12) and an observation phase (Weeks W13-W24). Eligible patients will be randomly allocated into three groups at a ratio of 1:1:1: Test Group 1, Test Group 2, or the Control Group. And clinical cure, recurrence rates, adverse events, vital signs, laboratory tests, drug exposure doses, premature withdrawals will be analyzed.

Timeline

Start
2024-07
Primary completion
2025-01
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Peginterferon α-2b Protein / enzyme biologic 36 ug Other
Subject Peginterferon α-2b Protein / enzyme biologic 180 ug Other